On June 16, 2025, HC Wainwright & Co. analyst Joseph Pantginis reaffirmed a "Buy" rating for Celldex Therapeutics (CLDX, Financial), maintaining a price target of $50.00 USD. This decision reflects continued confidence in the company's performance and future prospects.
The price target remains unchanged from its previous valuation, indicating consistent expectations for the stock's trajectory. As of this report, there has been no alteration in the percentage change of the price target, suggesting stability in the analyst's forecast for Celldex Therapeutics (CLDX, Financial).
Celldex Therapeutics (CLDX, Financial) continues to hold attention as a promising entity within the biopharmaceutical sector, with HC Wainwright & Co.'s affirmation of the "Buy" rating reinforcing positive sentiment among investors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Celldex Therapeutics Inc (CLDX, Financial) is $58.54 with a high estimate of $90.00 and a low estimate of $31.00. The average target implies an upside of 183.96% from the current price of $20.62. More detailed estimate data can be found on the Celldex Therapeutics Inc (CLDX) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Celldex Therapeutics Inc's (CLDX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Celldex Therapeutics Inc (CLDX, Financial) in one year is $16.95, suggesting a downside of 17.78% from the current price of $20.615. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Celldex Therapeutics Inc (CLDX) Summary page.